We can't find the internet
Attempting to reconnect
12985.1;6 PFLS-LS
Design, optimization and validation of compounds against cancer-Initiating cells.
Résumé
Design, optimization and validation of compounds against cancer-Initiating cells.
Textes supplémentaires
Abstract
This CTI project aims at identifying a preclinical candidate and generate a selection of back-up compounds to treat brain cancer, in order to accelerate and improve the development programs of Stemergie Biotechnology SA. The combination of the unique technology expertise of Stemergie in cancer-initiating cells with the medicinal chemistry technologies and know-how of the Carreira Group at the ETH Zurich shall enable the development of novel drug candidates to treat brain cancer patients.
Participants
Erick M. Carreira
Kontaktperson
carreira@org.chem.ethz.ch
ETHZ D-CHAB Erick M. Carreira Wolfgang-Paulistr. 10 8093 Zürich ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2011-11-14
- Date de fin
- 2014-05-01
- Coûts totaux approuvés
- CHF 614000.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Nicht aufteilbare / nicht zuteilbare Forschung
Disciplines de recherche
- T490 Biotechnology 100.0%